Use of Sacubitril/Valsartan in Heart Failure
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis | JACC: Heart Failure
Frontiers | Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum
New heart failure agent doubles mortality benefit of ACE inhibitors - PACE-CME
Emerging Mechanisms in the Management of Heart Failure With Reduced Ejection Fraction
PARADISE MI Trial: Is Sacubitril/valsartan (Entresto) useful in patients with acute MI? – Visualmed
Clinical Trial and Biomarker Data | ENTRESTO® (sacubitril/valsartan) | HCP
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure | Circulation
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial - Bhatt - 2021 - European Journal of Heart Failure - Wiley Online Library
PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF - PACE-CME
Clinical Trial and Biomarker Data | ENTRESTO® (sacubitril/valsartan) | HCP
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF | JACC: Heart Failure
CardsJC: PARAGON-HF Trial Journal Club - Cardionerds
Neprilysin: Indications, Expectations, and Challenges | Revista Española de Cardiología
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial - The Lancet Diabetes & Endocrinology
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women - ScienceDirect
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF - ScienceDirect
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of
Emerging Mechanisms in the Management of Heart Failure With Reduced Ejection Fraction
Understanding the early mortality benefit observed in the PARADIGM-HF | VHRM
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint | Novartis
The PARADIGM-HF trial (reproduced with permission from Wolters Kluwer). 6 | Download Table
Clinical Trial and Biomarker Data | ENTRESTO® (sacubitril/valsartan) | HCP
